Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron Pharmaceuticals Inc.

www.regeneron.com

Latest From Regeneron Pharmaceuticals Inc.

LentiGlobin Hogs The Limelight At CHMP’s First Amsterdam Meeting

An opinion on whether bluebird bio’s transfusion-dependent β-thalassemia gene therapy, LentiGlobin, should be granted an EU marketing authorization is due this week as the EMA’s key scientific committee, the CHMP, meets for the first time in Amsterdam.

Europe Approvals

Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer

Interview: Tesaro Chief Medical Officer Martin Huber addresses dostarlimab GARNET data and provides an update on integration with GlaxoSmithKline.

Research & Development Cancer

Adios To Alcon In April As Novartis Confirms Spin-Off Date

With the eye-care business set for its own stock exchange listings next month and the future of Sandoz the subject of much discussion, Novartis' plan to be a pure play pharma firm moves ever closer.

Strategy Ophthalmic

Biohaven Pays $105m For Turbo Boost In Migraine Drug Review Race

Biohaven has acquired a priority review voucher from GW Pharma to accelerate the US review of rimegepant, its oral CGRP receptor antagonist for migraine. The firm is competing with Allergan and Lilly in a race to get the next oral treatment approved.

Drug Review Neurology
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Infectious & Viral Diseases
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Regeneron Pharmaceuticals Inc.
  • Senior Management
  • Leonard S Schleifer, MD, PhD, Pres. & CEO
    Robert E Landry, SVP, Fin. & CFO
    George D Yancopoulos, MD, PhD, Pres. & CSO
  • Contact Info
  • Regeneron Pharmaceuticals Inc.
    Phone: (914) 847-7000
    777 Old Saw Mill River Rd.
    Tarrytown, NY 10591
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register